Drugs in MeSH Category Anti-Infective Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	MEPRON	atovaquone	SUSPENSION;ORAL	020500-001	Feb 8, 1995	AB	RX	Yes	Yes
Sciegen Pharms	METRONIDAZOLE	metronidazole	GEL;VAGINAL	216750-001	Dec 31, 2024	AB	RX	No	No
Rising	SULFASALAZINE	sulfasalazine	TABLET;ORAL	219046-001	Nov 4, 2025	AB	RX	No	No
Hetero Labs Ltd Iii	ATOVAQUONE	atovaquone	SUSPENSION;ORAL	210692-001	Oct 11, 2018	AB	RX	No	No

Market dynamics and patent landscape for anti-infective agents (NLM MeSH Class)

Last updated: June 29, 2026

Anti-infective agents in NLM MeSH class groups a large, commercially volatile segment where patent expiry, FDA regulatory exclusivity, and US generic entry risk are driven by (1) rapidly evolving resistance-driven pipelines, (2) frequent formulation and manufacturing “evergreening” IP, (3) dense Orange Book coverage around original approvals and line extensions, and (4) Paragraph IV strategy at scale for top-selling antibiotics and antivirals. For business planning, the dominant pattern across this therapeutic class is a shift from single-molecule patent estates to portfolio estates: drug substance plus salt/polymorph plus dosage form plus method-of-use plus manufacturing process, layered with regulatory exclusivities that postpone or accelerate generic entry.

How do market dynamics shape patent value in anti-infective agents?

Market dynamics in anti-infective agents are characterized by a high-value window around launch and a compressed competitive runway after patent loss, with revenue often concentrated in branded stewardship, payer coverage, and inpatient or specialty procurement. Patent value tracks not only legal life but also clinical positioning, label scope, and guideline adoption.

Which anti-infective subsegments show the highest revenue volatility post-launch?

Key revenue drivers in this class tend to cluster in:

• Antivirals (seasonality and variant cycles; label expansions)
• Antibiotics for resistant infections (restricted formularies; center-of-excellence purchasing)
• Antifungals (indication-driven procurement)
• Antiparasitics with narrower indication labels (less competitive but slower switching)

These dynamics affect patent strategy. Courts and the FDA look for whether the “same drug” concept is preserved across salts, polymorphs, combination products, and dosing regimens. IP that narrows to one formulation or one narrow indication tends to have less revenue buffering than broad composition-of-matter or method-of-use claims.

What commercial patterns determine when generic entry actually hits?

Commercial entry timing is often less about the calendar and more about:

• Immediate-to-market generic ability (manufacturing readiness for sterile injectables, high-viscosity oral suspensions, complex salts)
• Bioequivalence feasibility (solubility and stability constraints)
• Payer reimbursement switches (switching barriers)
• Supply chain capacity (especially for injectable anti-infectives)

In practical terms, even where a Paragraph IV challenge is filed early, market entry may be delayed by manufacturing scale-up and supply qualification bottlenecks tied to hard-to-make formulations.

How do FDA pathways influence generic launch risk in anti-infectives?

Regulatory pathway affects exclusivity and Orange Book listing density:

• New molecular entity approvals often pair composition claims with additional formulation patents.
• 505(b)(2) approvals can inherit or rely on prior art, but still generate their own listed patents, which can complicate generic certification outcomes.
• Accelerated approvals and supplemental indications can extend economic life through label expansion, even when the underlying patent estate is nearing expiration.

What patents protect anti-infective agents: composition, formulations, and methods of use?

Protection in anti-infective agents typically spans four layers that map to how generics design around:

1. Composition of matter (drug substance)
2. Formulation (salt, polymorph, particle size, dosage form, release profile)
3. Method-of-use (treatment of a specific infection type, patient population, dosing regimen)
4. Manufacturing and process (solid-state controls, sterile manufacturing parameters, impurities)

How many patents cover anti-infective “top brands” in practice?

For many blockbuster anti-infectives, Orange Book coverage often numbers in the dozens across multiple patents per “ingredient” record. Density is frequently highest when:

• The marketed product is a complex formulation (injectable, extended-release, combination)
• There are multiple NDCs for strengths and packaging
• The brand has multiple supplements tied to specific resistant pathogens or dosing regimens

Which patent types most often block generic entry?

The most litigation-relevant blockers across anti-infectives tend to be:

• Composition-of-matter patents (hard to design around without changing the active ingredient)
• Formulation patents tied to specific salts/polymorphs or release characteristics
• Method-of-use patents that keep label-protected indications out of reach

Manufacturing process patents can create additional friction, but generic manufacturers often focus on clearing ANDA design-around and certification rather than replicating exact process details.

When does patent exclusivity expire for anti-infective agents, and what drives the launch window?

Patent expiration and exclusivity are distinct levers. In anti-infectives, the launch window is often defined by the later of:

• Patent expiration for the relevant Orange Book-listed patents
• Regulatory exclusivity for the relevant approval (including new chemical entity, new clinical investigation, or biologics-related exclusivities when applicable)
• Settlement-driven entry dates in Paragraph IV disputes

How long is the regulatory exclusivity timeline for brand anti-infectives?

Typical patterns (varies by approval category and supplement history):

• 5 years of NCE-like data exclusivity for qualifying new chemical entities in US practice
• 3 years for new clinical investigations for certain supplemental approvals
• Patent life can extend beyond these periods, but regulatory exclusivity often controls early ANDA reliance timing

In anti-infectives, label expansions via supplemental approvals can produce additional exclusivity “islands” when they include required clinical data for specific claims.

What is the Orange Book status of anti-infective drugs at a generic entry point?

At the generic entry point, the Orange Book status typically shows:

• “Patents Expired” statuses for earlier entries while later-life patents remain active
• Staggered expiration across different NDCs and strengths
• Multiple patents with different “listed” status, creating mixed certification landscapes for would-be generic entrants

This creates a common scenario: a generic can be ready on composition but still face formulation or method-of-use barriers.

Which companies are challenging anti-infective patents via Paragraph IV, and what does that mean for launch timing?

Paragraph IV filings are a primary mechanism for accelerated generic entry in anti-infectives. The impact depends on:

• Whether the brand asserts key patents with strong validity prospects
• Whether the case settles with an agreed entry date
• Whether the generic obtains FDA approval at the earliest statutory window

What Paragraph IV patterns are common in anti-infective categories?

Typical patterns include:

• Multiple filers targeting the same brand, creating competitive pressure and sometimes multiple litigations
• Targeting high-margin strengths or most broadly reimbursed formulations first
• Entering with a design-around strategy (alternate salt form, different release profile, or carve-out of protected indications via label)

How do settlement agreements affect actual generic launch?

Settlement agreements can shift entry from the statutory outcome to a later date. In anti-infectives, settlements are often used to:

• Avoid prolonged litigation cost while preserving branded market share
• Coordinate supply and distribution readiness for the agreed launch date
• Manage indemnification and label timing around method-of-use barriers

What formulation patents protect anti-infective drug products?

Formulation IP is central in anti-infectives because stability, solubility, and tolerability directly affect patient adherence and clinical outcomes. Common protected elements include:

• Salt selection and corresponding physicochemical properties
• Polymorph control and solid-state stability
• Particle size or morphology for solubility improvement
• Excipients and matrix systems for sustained release
• For injectables: sterile manufacturing controls, impurity limits, and specific packaging constraints

How do formulation patents affect bioequivalence and design-around strategies?

Generic applicants often attempt:

• Alternate acceptable salt forms
• Different particle sizes that remain bioequivalent while trying to avoid literal claim coverage
• Different excipient systems and manufacturing controls

Litigation frequently turns on claim construction for “substantially” defined parameters and on whether generic products fall within the protected ranges for key physicochemical attributes.

What method-of-use patents are used to protect anti-infective indications?

Method-of-use protection plays outsized economic roles in anti-infectives because label scope determines where sales occur. Method-of-use patents often cover:

• Specific resistant pathogen categories or infection sites
• Patient subsets (e.g., renal impairment, pediatric populations)
• Treatment duration regimens (dosing schedule and course length)
• Combination therapy sequences or co-administration instructions

When a generic launches, can it carve out protected indications?

In US practice, a common outcome is:

• Generic approval with labeling carve-outs for patented indications
• Continued branded sales in protected label segments
• A slower erosion of revenue if the protected indication is the key reimbursement driver

This creates a “partial entry” market dynamic: generic price compression may spread even if the label carve-out remains in place.

What patent litigation affects anti-infective drug markets?

Anti-infective patent litigation is typically concentrated around the Orange Book-listed patents tied to composition, formulation, and key indications. Business exposure hinges on:

• Whether the asserted patents include broad composition claims or narrow formulation claims
• Win/loss outcomes at early stages (PI motions, claim construction)
• Whether settlements include agreed dates and licensing permissions

What litigation timeline patterns matter for planning?

A common set of milestones:

• ANDA acceptance and patent list certifications
• Initial pleadings and claim construction schedules
• Markman outcomes shaping design-around viability
• Settlement windows near key litigation deadlines

The commercial implication: even when a patent seems close to expiry, early litigation outcomes can accelerate or delay real-world entry.

What generic entry risks exist for anti-infective agents?

Generic entry risk is best modeled as a function of three variables:

1. Patent estate strength and remaining term of the most relevant Orange Book patents
2. Probability of successful design-around for formulation/method-of-use claims
3. Litigation and settlement status affecting FDA approval-to-market conversion

Which anti-infective formats face the most manufacturing or regulatory entry friction?

Higher friction cases:

• Sterile injectables (aseptic manufacturing, particulate control)
• Highly specialized solid dosage forms with strict dissolution profiles
• Combinations with multiple actives and complex ratio control

Even if legal barriers fall, manufacturing qualification can delay entry and preserve branded revenue for longer than the purely legal timeline.

How do anti-infective patent estates compare across antiviral, antibiotic, antifungal, and antiparasitic segments?

Patent strategy varies by mechanism and development economics:

• Antivirals: often see multiple supplemental indications and resistance-driven label expansions, increasing method-of-use and combination coverage.
• Antibiotics: resistance phenotypes can drive narrow method-of-use claims and tailored dosing regimens.
• Antifungals: solid-state properties and long treatment durations make formulation IP and tolerability-related labeling more valuable.
• Antiparasitics: fewer blockbuster label expansions in many cases, but strong composition or combination IP can remain economically significant.

What does portfolio vs single-molecule IP look like?

• Portfolio estates (multiple patents across multiple NDCs and strengths) tend to reduce sudden entry risk.
• Single-molecule estates often create sharper step-function entry timing when the core composition expires, unless formulation or method-of-use patents add a later barrier.

Where do anti-infective patents concentrate geographically: US vs EU vs other markets?

Global anti-infective commercialization typically relies on jurisdictional parallel protection:

• US patent filings create Orange Book-driven ANDA leverage
• EU and UK parallel rights affect market access and can shape licensing posture even if US entry is delayed
• Emerging markets often follow local regulatory timelines that can differ from US exclusivity

For business planning, the key point is that US Orange Book status is the primary trigger for ANDA-driven entry in the US market, while other jurisdictions determine revenue capture outside the US.

What is the competitive landscape among brands and generics in anti-infective agents?

Competition dynamics in anti-infectives are shaped by:

• Resistance and guideline updates that shift standard-of-care usage
• Stewardship programs that influence which products get reimbursed
• Rapid follow-on approvals (new dosing schedules, new combinations)
• Generic entry timing and label carve-outs

The competitive consequence: even a generic with FDA approval may not fully capture usage if it cannot substitute clinically or payer-favored protocols.

How strong is the patent estate for anti-infective drugs, and how should it be scored?

A practical “strength” scoring model for anti-infectives weights:

• Remaining patent term of the last-to-expire Orange Book patents
• Claim breadth (composition vs specific formulation parameters)
• Litigation posture (asserted patents and venue history)
• Settlement likelihood and presence of multiple challengers

Because anti-infectives often have dense Orange Book coverage, strength tends to be highest when the last-to-expire listed patents are composition or broad method-of-use rather than narrow formulation.

What data points determine revenue exposure to patent expiry in anti-infective markets?

Revenue exposure is tied to:

• NDC-level sales concentration by strength and dosage form
• Indication-level sales mix (protected vs unprotected indications)
• Dependence on stewardship-restricted usage
• Contracting and hospital formulary placement that can delay substitution

The most exposed branded segments are those where:

• The patented claim scope is narrow enough to allow label carve-outs
• The formulation is easy to match for generics
• Litigation ends in quick settlements aligned with early expiry dates

Key Takeaways

• Anti-infective patent value is driven by dense Orange Book coverage spanning composition, formulation, and method-of-use, with market timing influenced by manufacturing and label carve-outs.
• Generic entry risk in this class is highest when the last-to-expire listed patents are narrow formulation claims or when method-of-use coverage can be avoided via labeling.
• Market outcomes often diverge from legal timelines due to supply readiness and payer stewardship dynamics.
• For planning, focus on the last-to-expire US Orange Book patents, the most commercially relevant NDCs and indications, and the litigation and settlement posture that governs approval-to-launch conversion.

FAQs

1) How do anti-infective NDC-level Orange Book listings change generic certification strategy?

Orange Book listings tied to specific NDCs and strengths can force different ANDA certification outcomes, creating staggered clearance for strengths even when the active ingredient is the same.

2) Do method-of-use patents in anti-infectives stop FDA approval or only restrict labeling?

Method-of-use patents typically constrain labeling. Generics can sometimes launch with carve-outs, depending on the patent coverage and certification outcomes.

3) What design-around approaches are most common for salt and polymorph formulation patents?

Common approaches include switching to a non-covered salt, targeting a different polymorph form, or adjusting particle size to avoid literal claim ranges while preserving bioequivalence.

4) What factors most affect whether a Paragraph IV challenge leads to an earlier or later market launch?

Key drivers are settlement terms, patent assertion focus (broad vs narrow claims), and generic manufacturing readiness for formulation and presentation.

5) How do resistance-driven label changes affect patent estate monetization?

Resistance-driven label expansions can extend method-of-use coverage and create new IP-linked indication value, delaying substitution even as older indications face generic pressure.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations.
2. U.S. FDA. Guidance for Industry: Paragraph IV Certifications and Related Matters (ANDA litigation framework).
3. U.S. FDA. Drugs@FDA (approval and exclusivity information for marketed products).